Repligen

Historical price data

Repligen is a publicly traded, revenue-generating technology leader focused on innovating bioprocessing workflows for biologic drug manufacturing. Founded in 1981, the company has evolved from its academic roots into a $6.31B market cap enterprise through a strategy of organic product development and strategic acquisitions, building a comprehensive portfolio across chromatography, filtration, and fluid management. Its products are essential, consumable-driven tools used across the industry, making its growth tied to biopharmaceutical manufacturing capacity and the adoption of process intensification, rather than the success of any single drug. Repligen's position as a critical enabler in a high-growth market provides a resilient and scalable business model.

Repligen's integrated bioprocessing platform provides critical enabling technologies across four core areas: Chromatography (KRM systems), Filtration (TFF, ATF), Fluid Management (single-use assemblies, containers), and Process Analytics (CTech systems), designed to accelerate and intensify the manufacture of biologic drugs.

Repligen competes with full-spectrum bioprocessing giants like Cytiva (Danaher), Thermo Fisher Scientific, and Sartorius. It differentiates through deep specialization, first-to-market innovations in areas like TFF and perfusion, and a strategy of providing integrated workflow solutions rather than standalone products.